PURPOSE: Exercise is becoming readily accepted as a beneficial adjunct therapy to maintain or enhance quality of life in breast cancer patients undergoing adjuvant chemotherapy. An essential precursor to these studies is to investigate whether exercise modulates the antitumor efficacy of chemotherapeutic agents. EXPERIMENTAL DESIGN:Athymic female mice were transplanted with MDA-MB-231 breast xenografts and randomly assigned to one of four groups (n = 21 per group): (a) control, (b) exercise-only, (c) doxorubicin-only, or (d) exercise + doxorubicin. Exercise groups performed progressive treadmill running up to 18 m/min at 0% grade for 45 minutes, 5 d/wk for 8 weeks. RESULTS:Tumor growth delay was significantly longer in the doxorubicin-only and exercise + doxorubicin groups compared with the control (median 42 versus 25 days, P = 0.0082; 36 versus 25 days, P = 0.029, respectively) and exercise-only groups (median 42 versus 25 days, P = 0.029; 36 versus 25 days, P = 0.080, respectively). There was no significant difference between the doxorubicin-only and exercise + doxorubicin groups (median 42 versus 36 days, P = 0.33), suggesting that moderate intensity exercise does not significantly influence doxorubicin-induced tumor growth delay. CONCLUSION: These studies are essential to fully understand the safety and application of exercise as a supportive intervention in cancer control.
RCT Entities:
PURPOSE: Exercise is becoming readily accepted as a beneficial adjunct therapy to maintain or enhance quality of life in breast cancerpatients undergoing adjuvant chemotherapy. An essential precursor to these studies is to investigate whether exercise modulates the antitumor efficacy of chemotherapeutic agents. EXPERIMENTAL DESIGN: Athymic female mice were transplanted with MDA-MB-231 breast xenografts and randomly assigned to one of four groups (n = 21 per group): (a) control, (b) exercise-only, (c) doxorubicin-only, or (d) exercise + doxorubicin. Exercise groups performed progressive treadmill running up to 18 m/min at 0% grade for 45 minutes, 5 d/wk for 8 weeks. RESULTS:Tumor growth delay was significantly longer in the doxorubicin-only and exercise + doxorubicin groups compared with the control (median 42 versus 25 days, P = 0.0082; 36 versus 25 days, P = 0.029, respectively) and exercise-only groups (median 42 versus 25 days, P = 0.029; 36 versus 25 days, P = 0.080, respectively). There was no significant difference between the doxorubicin-only and exercise + doxorubicin groups (median 42 versus 36 days, P = 0.33), suggesting that moderate intensity exercise does not significantly influence doxorubicin-induced tumor growth delay. CONCLUSION: These studies are essential to fully understand the safety and application of exercise as a supportive intervention in cancer control.
Authors: Lee W Jones; Benjamin L Viglianti; Jessica A Tashjian; Sejal M Kothadia; Stephen T Keir; Stephen J Freedland; Michael Q Potter; Eui Jung Moon; Thies Schroeder; James E Herndon; Mark W Dewhirst Journal: J Appl Physiol (1985) Date: 2009-12-03
Authors: Ana I Faustino-Rocha; Adelina Gama; Paula A Oliveira; Antonieta Alvarado; Maria J Neuparth; Rita Ferreira; Mário Ginja Journal: Clin Exp Med Date: 2016-04-19 Impact factor: 3.984
Authors: Juan Garona; Marina Pifano; Maria B Pastrian; Daniel E Gomez; Giselle V Ripoll; Daniel F Alonso Journal: Clin Exp Metastasis Date: 2016-05-05 Impact factor: 5.150
Authors: Vernon W Dolinsky; Kyle J Rogan; Miranda M Sung; Beshay N Zordoky; Mark J Haykowsky; Martin E Young; Lee W Jones; Jason R B Dyck Journal: Am J Physiol Endocrinol Metab Date: 2013-05-21 Impact factor: 4.310
Authors: Marta Smeda; Kamil Przyborowski; Bartosz Proniewski; Agnieszka Zakrzewska; Dawid Kaczor; Marta Stojak; Elzbieta Buczek; Zenon Nieckarz; Jerzy A Zoladz; Joanna Wietrzyk; Stefan Chlopicki Journal: Am J Cancer Res Date: 2017-09-01 Impact factor: 6.166